Appendix 4C Cashflow Statementand Quarterly Activities Report

Appendix 4C Cashflow Statementand Quarterly Activities Report

The Calmer Co. International Limited (ASX: CCO) submits the following Activities Report and Appendix 4C Cash Flow Statement for the three-month period ended 30th September 2026.

Highlights

  • Record quarterly revenue of $2.44 million, up 42% on the prior quarter, driven by wholesale and B2B sales of $832k (Q4 FY26: $306k), with retail revenue up 25% to $975k.
  • Retail revenue increased 25% QoQ to $975,037, driving Australian revenue up 24% to $1,202,311, underpinned by growth in both Coles and Woolworths.
  • United States revenue of $1,197,854, contributing 49% of Group revenue, reflecting the timing of wholesale and B2B orders in the quarter.
  • Wholesale sales of $831,569 for the quarter (Q4 FY26: $305,740), with approximately 91% generated in the United States.
  • Cash receipts from customers of $1.79 million, with net operating cash outflows improving 6% to $755,000 and cash of $953,000 at quarter end following the $1.21 million capital raise completed in the quarter.
  • Inventory (including prepaid) maintained at $1.5 million, positioned to support demand across wholesale, B2B and retail channels into FY27.
  • Continued cost discipline, with advertising and marketing expenditure (OPEX) improving 56% quarter-on-quarter to $112k, representing 5% of Group revenue.
  • With diversified revenue streams, a strengthened retail base and growing traction in higher-value channels, The Calmer Co. moves into Q2 FY27 focused on executing its growth plan and progressing toward cash flow breakeven.

CEO Zane Yoshida, said,

“The September quarter marked an important milestone for The Calmer Co., with record revenue of $2.44 million, up 42% quarter-on-quarter. This result demonstrates the growing strength of our diversified business model across Australian retail, e-commerce and international wholesale markets.

Wholesale and B2B ingredients revenue increased to $832,000 from $306,000 in the prior quarter, supported by demand for premium kava ingredients, including CO₂ extracts, particularly in the United States. Scaling this higher-value channel remains central to our strategy to improve Group margins and build a more predictable revenue base.

Australian retail also delivered strong growth, with retail revenue up 25% quarter-onquarter, supported by Coles and Woolworths. The planned introduction of Fiji Kava® FZZR™ into Coles during Q2 FY27 provides a further opportunity to broaden consumer access to kava products.

We maintained our focus on disciplined cash and cost management, with net operating cash outflows improving 6% to $755,000. As we progress through FY27, our priorities are to scale wholesale ingredients and branded consumer products, strengthen supply chain efficiency and working capital management, and progress toward quarterly cash flow breakeven.”

Click here for the full ASX Release

This article includes content from The Calmer Co. International Limited, licensed for the purpose of publishing on Investing News Australia. This article does not constitute financial product advice. It is your responsibility to perform proper due diligence before acting upon any information provided here. Please refer to our full disclaimer here.

CCO:AU
The Conversation (0)
Coles Orders Fiji Kava® FZZR™ – First Flavoured Kava Product to Launch in Australia

Coles Orders Fiji Kava® FZZR™ – First Flavoured Kava Product to Launch in Australia

The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, refers to its ASX announcement of 24 June 2026 and is pleased to advise that Coles has placed its initial order... Keep Reading...
Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Numinus Wellness Inc. Announces Fourth Quarter Fiscal 2025 Results and Provides Corporate Update

Q4 Fiscal 2025 Highlights Revenue of $2.3 million, a 29.0% increase over Q3 2025 Gross profit of $1.4 million, compared to a gross profit of $0.8 million in Q3 2025 Cash position of $0.5 million as of August 31, 2025 Subsequent to Quarter End On April 18, 2026, President Donald Trump signed an... Keep Reading...
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million

Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
Gloved hand holds a cluster of brown mushrooms growing from a gray substrate block.

Psychedelics Market Trends: H1 2026 Review and Forecast

The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
A pill bottle with US flag and coloured pills.

Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets

The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
Dried mushrooms surrounded by translucent capsules on a white background.

Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain

On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...

Interactive Chart

Latest Press Releases

Related News